Free Trial

Seelos Therapeutics (SEEL) Insider Trading & Ownership

Seelos Therapeutics logo
$0.35 -0.04 (-10.14%)
(As of 11/19/2024 ET)

Seelos Therapeutics (NASDAQ:SEEL) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.08%
Number Of
Insiders Buying
(Last 3 Years)
2
Amount Of
Insider Buying
(Last 3 Years)
$64,857.60
Number Of
Insiders Selling
(Last 3 Years)
0
Get SEEL Insider Trade Alerts

Want to know when executives and insiders are buying or selling Seelos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SEEL Insider Buying and Selling by Quarter

Seelos Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2022Daniel J O'connorDirectorBuy4$2,342.40$9,369.60  
3/31/2022Raj MehraInsiderBuy17$3,264.00$55,488.00  
(Data available from 1/1/2013 forward)

SEEL Insider Trading Activity - Frequently Asked Questions

The list of insiders at Seelos Therapeutics includes Daniel J O'connor, and Raj Mehra. Learn more on insiders at SEEL.

1.08% of Seelos Therapeutics stock is owned by insiders. Learn more on SEEL's insider holdings.

Seelos Therapeutics Key Executives

  • Dr. Raj Mehra J.D. (Age 64)
    Ph.D., CEO, Founder, President & Director
    Compensation: $599.53k
  • Mr. Michael J. Golembiewski (Age 52)
    Chief Financial Officer
    Compensation: $388.2k
  • Mr. Anthony Marciano
    Chief Communications Officer
  • Gopal Krishna Ph.D.
    Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D.
    Chief Medical Officer
  • Ms. Karen Fusaro
    Senior VP & Head of Clinical Operations


This page (NASDAQ:SEEL) was last updated on 11/20/2024 by MarketBeat.com Staff
From Our Partners